Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Oral food challenge

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    28 result(s) found for: Oral food challenge. Displaying page 1 of 2.
    1  2  Next»
    EudraCT Number: 2017-005060-18 Sponsor Protocol Number: 2016AL002 Start Date*: 2018-03-09
    Sponsor Name:Manchester University NHS Foundation Trust
    Full Title: The Role of Uric Acid Metabolism in Pathogenesis of Anaphylaxis: the Effect of Allopurinol on Experimentally-induced Allergic Reaction to Peanut in Peanut Allergic Adults- a randomised, double-blin...
    Medical condition: Determination of the Lowest Observed Adverse Event level dose (LOAEL)of peanut in individual suffering with peanut allergy, after treatment with allopurinol.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10001738 Allergy LLT
    20.0 10021428 - Immune system disorders 10016946 Food allergy PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2017-001334-26 Sponsor Protocol Number: ARC008 Start Date*: 2018-01-17
    Sponsor Name:Aimmune Therapeutics, Inc.
    Full Title: A MULTICENTER, OPEN-LABEL, LONG-TERM SAFETY STUDY OF AR101 CHARACTERIZED ORAL DESENSITIZATION IMMUNOTHERAPY IN SUBJECTS WHO PARTICIPATED IN A PRIOR AR101 STUDY
    Medical condition: Peanut Allergy
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Prematurely Ended) SE (Completed) ES (Completed) DE (Completed) FR (Prematurely Ended) NL (Prematurely Ended) IT (Completed)
    Trial results: View results
    EudraCT Number: 2017-005038-53 Sponsor Protocol Number: FIM-PRU-2018-01 Start Date*: 2019-05-16
    Sponsor Name:Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina Y Salud (FIMABIS)
    Full Title: Randomized double-blind, placebo-controlled study evaluate the efficacy and mechanisms involved in immunotherapy Sublingual specifies with Pru p 3 (Pru p 3-ITSL) in patients with allergy to nsLTP w...
    Medical condition: LTP syndrome.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10016946 Food allergy PT
    Population Age: Children, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-005534-36 Sponsor Protocol Number: Scope Start Date*: 2008-02-04
    Sponsor Name:King's College Hospital [...]
    1. King's College Hospital
    2. King's College London
    Full Title: The effect of Exenatide on satiety, metabolic parameters and regional brain activation in response to nutrient ingestion in Type 2 diabetes.
    Medical condition: The brainﾒs response to food ingestion can be imaged and preliminary data suggest that these responses are different in the obese and insulin resistant. We will investigate the hypothesis that Exen...
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-000631-92 Sponsor Protocol Number: CQGE031A2208 Start Date*: 2011-12-07
    Sponsor Name:Novartis Pharma AG
    Full Title: A phase II, randomized, double-blind, placebo controlled, parallel design, dose ranging, multi-center trial of four levels of exposure of QGE031 s.c. for 16 weeks in subjects aged 18 years and olde...
    Medical condition: Peanut allergy
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021428 - Immune system disorders 10034202 Peanut allergy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Prematurely Ended) GB (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-005838-12 Sponsor Protocol Number: OC000459/004/05 Start Date*: 2006-03-30
    Sponsor Name:Oxagen Ltd
    Full Title: A PHASE II STUDY OF THE EFFICACY (AS ASSESSED BY BRONCHIAL ALLERGEN CHALLENGE) AND SAFETY OF OC000459 DOSED ORALLY (200mg BID WITH FOOD) IN SUBJECTS WITH ALLERGIC ASTHMA; IN A RANDOMISED, DOUBLE BL...
    Medical condition: Asthma
    Disease: Version SOC Term Classification Code Term Level
    8.1 10003553 Asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-004910-41 Sponsor Protocol Number: WellmuneElderlyStudy1.1 Start Date*: 2011-12-30
    Sponsor Name:University of Southampton
    Full Title: A Randomised Controlled Trial to assess a food supplement (baker’s yeast extract) to support immune function and prevent cold and flu symptoms in a 50 to 70 year old population
    Medical condition: We aim to assess the number and severity of Upper Respiratory Tract Infection(URTI)Symptoms reported by participants over a 90 day period commencing in January 2012 in 100 healthy 50-70 year olds p...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-003665-34 Sponsor Protocol Number: INP20-01 Start Date*: 2019-04-26
    Sponsor Name:InnoUP Farma SL
    Full Title: A multicenter double-blind, randomized, placebo-controlled phase I/II study to determine the safety, tolerability, potential efficacy and dose finding of INP20, an oral formulation for treatment of...
    Medical condition: Peanut allergy
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004870 10034202 Peanut allergy LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005339-56 Sponsor Protocol Number: CQGE031G12301 Start Date*: Information not available in EudraCT
    Sponsor Name:Novartis Pharma AG
    Full Title: A 52 week, multi-center, randomized, double-blind placebo-controlled study to assess the clinical efficacy and safety of ligelizumab (QGE031) in decreasing the sensitivity to peanuts in patients wi...
    Medical condition: Allergy, Peanut
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004870 10034202 Peanut allergy LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: FR (Prematurely Ended) ES (Ongoing) DE (Prematurely Ended) IT (Prematurely Ended) DK (Prematurely Ended) NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-004941-94 Sponsor Protocol Number: ARC004 Start Date*: 2017-05-05
    Sponsor Name:Aimmune Therapeutics, Inc.
    Full Title: PEANUT ALLERGY ORAL IMMUNOTHERAPY STUDY OF AR101 FOR DESENSITIZATION IN CHILDREN AND ADULTS (PALISADE) FOLLOW-ON STUDY
    Medical condition: Peanut Allergy
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: IE (Completed) GB (Completed) SE (Completed) DE (Completed) ES (Completed) NL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-000097-19 Sponsor Protocol Number: TRANCHE Start Date*: 2016-06-10
    Sponsor Name:Charité Universitätsmedizin Berlin
    Full Title: Open, comparative, randomized study on the efficacy, safety and bioavailability of highly concentrated inhaled epinephrine (4 mg L-epinephrine / ml, Infectokrupp® Inhal) versus epinephrine autoinje...
    Medical condition: Food allergy
    Disease:
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-002461-37 Sponsor Protocol Number: PEPITES Start Date*: 2015-12-17
    Sponsor Name:DBV Technologies
    Full Title: A double-blind, placebo-controlled, randomized phase III pivotal trial to assess the efficacy and safety of peanut epicutaneous immunotherapy with viaskin peanut in peanut-allergic children
    Medical condition: Peanut Allergy
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004870 10034202 Peanut allergy LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: IE (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-006950-30 Sponsor Protocol Number: CLOU064I12201 Start Date*: 2022-08-02
    Sponsor Name:Novartis Farmacéutica, S.A.
    Full Title: A one month, investigator and participant blinded study to investigate the efficacy and safety of remibrutinib (LOU064) at multiple dose levels in adult participants with peanut allergy
    Medical condition: Allergy, Peanut
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004870 10034202 Peanut allergy LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-002533-42 Sponsor Protocol Number: ARC002 Start Date*: 2021-12-07
    Sponsor Name:Aimmune Therapeutics, Inc.
    Full Title: Oral Desensitization to Peanut in Peanut-Allergic Children and Adults Using Characterized Peanut Allergen (CPNA) Peanut Oral Immunotherapy (OIT) Safety Follow-On Study
    Medical condition: Peanut Allergy
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2008-001714-24 Sponsor Protocol Number: BTA798-CL2-001 Start Date*: 2008-06-18
    Sponsor Name:Biota Scientific Management Pty Ltd
    Full Title: A Phase II, Double-Blind Placebo-Controlled Study to Determine the Prophylactic Efficacy of Oral BTA798 in an Experimental Rhinovirus Challenge Model
    Medical condition: BTA798 is an investigational drug being developed as a potential agent for treatment and prevention of the common cold.
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-001749-15 Sponsor Protocol Number: ARC005 Start Date*: 2019-05-21
    Sponsor Name:Aimmune Therapeutics , Inc.
    Full Title: Peanut Oral Immunotherapy Study of Early Intervention for Desensitization (POSEIDON)
    Medical condition: Peanut Allergy
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004870 10034202 Peanut allergy LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IE (Completed) FR (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2022-000215-31 Sponsor Protocol Number: S65796 Start Date*: 2022-05-24
    Sponsor Name:UZ Leuven
    Full Title: A monocentric academic trial comparing the diagnostic value of history taking and nasal lysine aspirin provocation test in the diagnosis of AERD in CRSwNP patients
    Medical condition: Aspirin-Exacerbated Respiratory Disease (AERD) in patients with Chronic RhinoSinusitis with Nasal Polyps (CRSwNP)
    Disease: Version SOC Term Classification Code Term Level
    25.1 100000004855 10075084 Aspirin-exacerbated respiratory disease LLT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-004257-41 Sponsor Protocol Number: ARC003 Start Date*: 2016-02-10
    Sponsor Name:Aimmune Therapeutics Inc.
    Full Title: PEANUT ALLERGY ORAL IMMUNOTHERAPY STUDY OF AR101 FOR DESENSITIZATION IN CHILDREN AND ADULTS (THE PALISADE STUDY)
    Medical condition: Peanut Allergy
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: SE (Completed) DE (Completed) GB (Completed) DK (Completed) IE (Completed) NL (Completed) ES (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-002031-26 Sponsor Protocol Number: RHMCHI065 Start Date*: 2013-06-25
    Sponsor Name:University Hospitals Southampton NHS Foundation Trust
    Full Title: Safety of Nasal Influenza Immunisation in Egg Allergic Children - The SNIFFLE study
    Medical condition: Children aged 24 months to (and including) 17 years with IgE-mediated food allergy to egg protein
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004870 10014315 Egg allergy LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-002916-42 Sponsor Protocol Number: PEOPLE-V712-303 Start Date*: Information not available in EudraCT
    Sponsor Name:DBV TECHNOLOGIES S.A.
    Full Title: Open-label Follow-up Study of the PEPITES Study to Evaluate the Long-term Efficacy and Safety of Viaskin® Peanut (PEOPLE Study)
    Medical condition: Peanut Allergy
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004870 10034202 Peanut allergy LLT
    Population Age: Children, Under 18 Gender: Male, Female
    Trial protocol: IE (Prematurely Ended) DE (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu May 15 23:58:28 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA